Breast-GPA and type of treatment predictors of survival in brain metastasis patients.

e13530Background: brain metastases (BM) occur in 15-30% of patients with metastatic breast cancer (MBC). In spite of improvements in the treatment, the development of BM is still being a major limitation of life expectancy and quality of life for many patients (P). Methods: ambispective analysis of MBC patients who developed single or multiple BM and were treated in a single cancer comprehensive center. Identification of patients and updates of follow up were performed through Radiation Oncology department registries and Pathology Records. Breast Graded Prognostic Assessment (GPA) was calculated according to Sperduto GPA (2012). Results: from 2007 to 2014, 133 patients were identified; 30(22.6%) were diagnosed at de novo IV stage. Median age at BM diagnosis 52.3 years (29.7-81); 53 (39.8%) were luminal (LT), 42 (31.6%) HER2 positive (Her2), 31 (23.3%) triple negative (TN) and 7 cases unknown. Median PFS was 28m and median time to BM after cancer diagnosis (TBM) was 41 m (71m in LT, 26m in Her-2 and 20 m i...